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AbstrAct
Objective To develop a simplified Finnegan Neonatal 
Abstinence Scoring System (sFNAS) that will highly 
correlate with scores ≥8 and ≥12 in infants being 
assessed with the FNAS.
Design, setting and participants This is a 
retrospective analysis involving 367 patients admitted to 
two level IV neonatal intensive care units with a total of 
40 294 observations. Inclusion criteria included neonates 
with gestational age ≥37 0/7 weeks, who are being 
assessed for neonatal abstinence syndrome (NAS) using 
the FNAS. Infants with a gestational age <37 weeks 
were excluded.
Methods A linear regression model based on the 
original FNAS data from one institution was developed to 
determine optimal values for each item in the sFNAS. A 
backward elimination approach was used, removing the 
items that contributed least to the Pearson’s correlation. 
The sFNAS was then cross-validated with data from a 
second institution.
results Pearson’s correlation between the proposed 
sFNAS and the FNAS was 0.914. The optimal treatment 
cut-off values for the sFNAS were 6 and 10 to predict 
FNAS scores ≥8 and ≥12, respectively. The sensitivity 
and specificity of these cut-off values to detect FNAS 
scores ≥8 and ≥12 were 0.888 and 0.883 for a cut-off of 
6, and 0.637 and 0.992 for a cut-off of 10, respectively. 
The sFNAS cross-validation resulted in a Pearson’s 
correlation of 0.908, sensitivity and specificity of 0.860 
and 0.873 for a cut-off of 6, and 0.525 and 0.986 for a 
cut-off of 10, respectively.
conclusion The sFNAS has a high statistical 
correlation with the FNAS, and it is cross-validated for 
the assessment of infants with NAS. It has excellent 
specificity and negative predictive value for identifying 
infants with FNAS scores ≥8 and ≥12.
IntrODuctIOn
The incidence of neonatal abstinence 
syndrome (NAS) has steadily increased since 
the 1970s and is now a significant public 
health problem.1–4 Tolia et al5 reported an 
almost fourfold increase in NAS neonatal 
intensive care unit (NICU) admissions 
from 7 cases/1000 admissions in 2004 to 27 
cases/1000 in 2013. The median length of 
stay for infants with NAS increased from 13 
to 19 days. The proportion of infants who 
received pharmacotherapy also increased, 
74% in 2004–2005 to 87% in 2012–2013, 
resulting in a 35% increase in hospital costs.2
Several scoring systems have been proposed 
to evaluate infants with NAS.6 These included 
the Finnegan Neonatal Abstinence Scoring 
System (FNAS), the Lipsitz tool,7 the Neonatal 
Withdrawal Inventory,8 the Neonatal Narcotic 
Withdrawal Index9 and so on. However there 
is no consensus as to which tool to use, the 
cut-off points for treatment and the interval 
between assessments.3 6 10 11
The FNAS has been the most commonly 
used scale for the last 40 years.3 4 10–12 The 
FNAS was developed in 19751 13 and consisted 
of 21 items allowing a thorough assessment 
of infants with NAS. The tool was analysed 
for interuser reliability (mean inter-rater reli-
ability coefficient of 0.82 (0.75–0.96)) and 
validated for the diagnosis of NAS. However, 
the lack of subsequent validation and inter-
rater reliability is a major concern regarding 
the FNAS.6 After its original publication, the 
FNAS was slightly modified in its form but not 
in content.14 15
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Research
strengths and limitations of this study
 ► A simplified scoring system (simplified Finnegan 
Neonatal Abstinence Scoring System  (sFNAS)) is 
proposed developed from a large data set and cross-
validated using a database from another institution.
 ► Cutoff values are provided for the sFNAS which 
predict the cutoff value.
 ► The retrospective nature of our study requires 
prospective validation of the inter-rater reliability of 
the sFNAS and also the clinical validity of this tool.
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Table 1 The steps for deriving the proposed simplified 
Finnegan Neonatal Abstinence Scoring System
Step Remove items
Pearson’s 
correlation after 
removal
Start with full model 1.000
1 Generalised convulsions 1.000
2 Nasal flaring 1.000
3 Frequent yawn 0.998
4 Myoclonic jerks 0.995
5 Excoriation 0.991
6 Fever 0.986
7 Sweating 0.979
8 Sneezing 0.967
9 Moro reflex 0.956
10 Mottling 0.944
Combine items or levels within 
items
11 Cry – excessive or continuous
Sleep – <2 hours or <3 hours
Tremors – combine all levels for 
each of disturbed and undisturbed
Respiratory rate – >60/min 
retraction or no retraction
Feed tolerance – regurgitation or 
projectile vomiting
Stools – loose or watery
0.921
12 Round values assigned to each 
item
0.914
Finnegan et al have proposed using three consecutive 
scores of 8 or higher, or two consecutive scores of 12 or 
higher, to initiate pharmacological treatment.1 13 15 Contig-
uous scores less than 8 are often used as a measure of read-
iness for weaning pharmacological therapy.16 The validity 
of the cut-off point of the FNAS was evaluated in 2010 by 
Zimmermann et al17 in term newborns without opiate expo-
sure. They found that 95% of the scores were less than 8, 
with some variability according to the day of life and time of 
day (lower at night); this led them to conclude that a value 
above 8 can be considered pathological. This study also 
supports the use of consecutive scores to identify infants 
who require pharmacological intervention.
The FNAS is a lengthy tool,8 18 and given the continued 
increase in the number of infants diagnosed with NAS 
our goal was to create a shortened and simplified version 
of Finnegan Scoring System (sFNAS) that will highly 
correlate with the original FNAS for an efficient clinical 
assessment.
MethODs
This retrospective study was conducted using data from 
two institutions, both level IV NICUs and regional referral 
centres for the respective area. The study was approved by 
the Institutional Review Board of the University of Louis-
ville and University of Kentucky. Data were collected from 
the electronic medical records at each institution. Inclu-
sion criteria included neonates with gestational age ≥37 
0/7 weeks, admission to the NICU for withdrawal after 
any in utero opioid exposure and assessment with the 
FNAS for signs of NAS. Infants with a gestational age less 
than 37 weeks and those with exposure to psychoactive 
substances without opioid exposure were excluded. At 
each institution, the nurses who performed the FNAS 
had training with experienced scorers (video, demonstra-
tion by trainer and reverse demonstration by trainee) and 
testing for reliability (trainer and trainee assess and score 
same infant) prior to being assigned care of infants with 
NAS; retraining in scoring with FNAS was done annually.
statistical analysis
Preliminary inspection of the frequency of each item on the 
FNAS and the total score was done. To derive our proposed 
sFNAS, items contributing least to the Pearson’s correla-
tion between the sFNAS and FNAS were eliminated until 
the correlation dropped below 0.95 (table 1). Multiple 
levels within the remaining items were then combined to 
one or fewer levels or subitems if the resulting impact on 
the correlation was negligible. This was done to simplify 
the scoring even further, which is particularly useful when 
distinguishing different levels of an item. Values assigned 
to each remaining item were obtained via linear regres-
sion and rounded to the nearest integer; the box shows 
the details of the statistical procedure. We estimated ORs 
to determine the associations between items. Generalised 
estimating equations (GEE) with robust SE estimation were 
used to account for repeated measurements or scores, from 
the same subject.19 Tests were two-sided at the 0.01 signifi-
cance level.
In the development of the sFNAS, the original FNAS 
scores of ≥8 or ≥12 were considered as the pharmacolog-
ical treatment cut-off values. Therefore, receiver operating 
characteristic (ROC) curves based on the accuracy of our 
shortened score to predict scores of ≥8 or ≥12 from the 
original FNAS were constructed. Optimal cut-off values 
for our sFNAS were then determined using the maximum 
proportion correctly classified (PCC). Sensitivities (Sn), 
specificities (Sp), positive predictive values (PPV) and nega-
tive predictive values (NPV) were also obtained, along with 
corresponding 95% CIs via the use of GEE.
To validate our sFNAS, we applied the scoring to the 
data from institution 2. Specifically, we computed for the 
Pearson’s correlations and tested classification propor-
tions, and the values of Sn, Sp, PPV, NPV and PCC were 
obtained. Analyses were conducted in SAS V.9.4.
results
The data comprised a whole year’s (2014) observations from 
185 subjects of institution 1 contributing a total of 27 447 
scores, and from 182 babies from institution 2 contributing 
a total of 12 847 scores. The number of observations per 
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box Detailed statistical steps and description in the development of the simplified Finnegan neonatal Abstinence scoring 
system (sFnAs)
steps 1–11
 ► Optimal values assigned to each item in our sFNAS were obtained via a linear regression model in which the items were used as predictors of the 
original FNAS. The full estimated regression model with all items is given by:
 ► (FNAS) ̂=b0+b1(Crying–Excessive high pitched)+b2(Crying–Continuous high pitched)+b3(Sleeps–<3 hours after feeding)+b4(Sleeps–<2 hours 
after feeding)+b5(Sleeps–<1 hour after feeding)+b6(Moro reflex–Hyperactive)+b7(Moro reflex–Markedly hyperactive)+b8(Tremors–
Mild: disturbed)+b9(Tremors–Moderate-severe: disturbed)+b10(Tremors–Mild: undisturbed)+b11(Tremors–Moderate-severe: 
undisturbed)+b12(Increased muscle tone)+b13(Myoclonic jerks)+b14(Generalised convulsions)+b15(Excoriation)+b16(Sweating)+b17(Fev
er–<101)+b18(Fever–>101)+b19(Frequent yawn)+b20(Mottling)+b21(Nasal stuffiness)+b22(Sneezing)+b23(Nasal flaring)+b24(Respiratory 
rate–>60/min)+b25(Respiratory rate–>60/min with retractions)+b26(Excessive sucking)+b27(Poor feeding)+b28(Regurgitation)+b29(Projectile 
vomiting)+b30(Stools–Loose)+b31(Stools–Watery)
 ► Here, (FNAS) ̂ is the predicted FNAS score and b0,…,b31 are estimated regression parameters, or the optimal values assigned to each level of each 
item. To develop the new scoring system, a backward elimination approach was used, removing the items that contributed least to the Pearson’s 
correlation between the shortened score and the original FNAS. Parameter estimates from the linear regression model correspond to optimal values 
for each item with respect to maximising the coefficient of determination, or R2; that is, the scores assigned to each item maximise the amount of 
variation in the observed original FNAS that can be explained by the given items. This corresponds to a maximisation of the Pearson’s correlation 
between the score from FNAS and the score that comprised the items in the regression model with their optimally assigned values.
 ► The steps in our elimination approach are given in table 1. Items were removed until the correlation dropped below 0.95 (step 10). Levels within the 
remaining items were then combined if the resulting impact on the correlation was negligible (step 11). This was done to simplify the scoring even 
further, which is particularly useful when it is difficult for scorers to distinguish between different levels of an item. Optimal values for each remaining 
item were rounded to the nearest integer.
step 12
 ► At the end of step 11, the estimated linear regression model is given by:
 ► (FNAS) ̂ = 0.93+2.00(Crying–Excessive or continuous high pitched)+1.43(Sleeps–<2 or 3 hours after feeding)+3.22(Sleeps–<1 hour after 
feeding)+1.33(Any disturbed tremors)+ 4.72(Any undisturbed tremors)+ 2.17(Increased muscle tone)+1.14(Nasal stuffiness)+1.26(Respiratory 
rate–>60/min, retraction or no retraction)+0.99(Excessive sucking)+1.99(Poor feeding)+2.11(Feed tolerance–Regurgitation or projectile 
vomiting)+1.99(Stools–Loose or watery).
 ► In order to simplify scoring with the sFNAS, we rounded the values in the above equation to the nearest integer. We note that b0 is a nuisance 
parameter, and although it rounds to 1 in the above equation, we do not include this value in the computation of the sFNAS.
baby in institution 1 ranged from 1 to 605, with a mean 
(SD) of 148 (116) and 25th, 50th and 75th percentiles of 
38, 153 and 210, respectively. The number of observations 
per baby in institution 2 ranged from 1 to 310, with a mean 
(SD) of 70 (59) and 25th, 50th and 75th percentiles of 18, 
60 and 106, respectively. The variability in the number of 
scores per infant was due to the inclusion of some infants 
in the study in the middle or end of their treatment course. 
Although the number of infants between institutions was 
similar, the total number of scores differed because in insti-
tution 2 scoring was changed to every 6 hours from every 
3 hours, when an infant showed improvement in scores 
following initiation of pharmacotherapy; the goal was to 
minimise disturbing the infant to promote more sleep and 
allow ad lib feedings.
Some signs differed in percentages of occurrence 
between the two institutions. The sign most frequently 
noted for both institutions was the increased muscle tone. 
The signs namely tremors, excessive cry, sleep <3 hours, 
respiratory rate >60/min and loose stools were observed 
in more than 10% of instances in both institutions. Gastro-
intestinal manifestations were more frequently observed 
in institution 2.
The backward elimination approach was applied to the 
data from institution 1 (table 1). The majority of items 
that were not retained were observed in less than 10% of 
instances; therefore, they did not contribute enough to the 
Pearson’s correlation in order to warrant their inclusion 
into the sFNAS. Mottling was an item that was present in 
more than 10% of the observations; however, its elimination 
did not greatly affect the Pearson’s correlation (table 1). 
The proposed sFNAS comprised 10 items as presented in 
table 2. The Pearson’s correlation of our sFNAS with the 
original FNAS is 0.914. The evaluation of the interrelated-
ness of the items that were removed and the items that were 
kept in the sFNAS are given in table 3. All items that were 
removed were significantly related to the items that were 
kept in the sFNAS, as demonstrated in table 3. Mottling is 
the item that was most significantly related to the others, 
as it had significant associations with 8 out of the 10 items 
that were retained in the sFNAS. The sFNAS predicted the 
original FNAS scores ≥8 or ≥12 or higher with a respective 
area under the ROC curve of 0.952 and 0.982. Based on the 
PCC, the optimal treatment cut-offs for our shortened scale 
are 6 and 10, respectively. The PCC for institution 1 for the 
cut-off values of 6 and 10 was 0.884 and 0.980, respectively, 
and comparable values of 0.867 and 0.920, respectively, for 
institution 2. Values of Sn, Sp, PPV, NPV and PCC are given 
in table 4.
For the statistical validation of the sFNAS, the scoring 
system applied to the data from institution 2 resulted in 
a Pearson’s correlation of 0.908 with the original FNAS. 
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Table 2 Items and scores in the proposed simplified 
Finnegan Neonatal Abstinence Scoring System
Item Value Scores
Cry Yes (excessive or 
continuous)
2
Tremors Tremors undisturbed (mild, 
moderate or severe)
5
Tremors disturbed (mild, 
moderate or severe)
1
Increased 
muscle tone
Yes 2
Sleep <1 hour
<2 or 3 hours
3
1
Nasal 
stuffiness
Yes 1
Respiratory 
rate
>60/min 1
Excessive 
sucking
Yes 1
Poor feeding Yes 2
Feed 
tolerance
Regurgitation or projectile 
vomiting
2
Stools Loose or watery stools 2
Ta
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Observed values for Sn, Sp, PPV, NPV and PCC from the 
use of sFNAS are also presented in table 4.
When deriving a new scale, it is likely that some values 
that are near the cut-off get incorrectly classified. There-
fore, we now look at the misclassified cases, that is, corre-
sponding sFNAS scores that were close to the FNAS 
cut-offs of 8 and 12. There were 20 197 FNAS scores of 
0–7 for the original data and 6969 for cross-validation 
data. Of these observations, 9.8% and 9.6%, respectively, 
corresponded to sFNAS cut-off score of 6. The total FNAS 
scores from 0 to 11 for the original and cross-validation 
data sets, respectively, were 26 497 and 10 940. Only 0.6% 
and 0.9% were misclassified, respectively, corresponding 
to sFNAS score of 10, the higher cut-off for sFNAS. Of 
the FNAS scores ≥8 (original data set: 7250 observations; 
cross-validation data: 5784), 8.4% and 9.7%, respectively, 
were misclassified as sFNAS=5, below the cut-off of 6 for 
sFNAS. As to FNAS scores ≥12 (original observations: 
950; cross-validation data: 1813), 196 or 20.6% and 397 or 
21.9%, respectively, were misclassified as sFNAS=9, lower 
than the higher sFNAS cut-off of 10.
DIscussIOn
We propose a simplified scoring system, the sFNAS, to eval-
uate infants with NAS. The sFNAS is a shortened FNAS 
derived by maximising its correlation with the original 
scale. Our scoring system consisting of 10 items provides a 
Pearson’s correlation of 0.914 with the original FNAS and 
a proposed cut-off of 6 and 10 (instead of 8 and 12). Using 
the proposed cut-off, the simplified scoring system provides 
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Table 4 Values obtained after applying the new scoring on the original data set (internal validation) and the data set from 
institution 2 (cross-validation)
Sn
(95% CI)
Sp
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
PCC
(95% CI) ROC
Internal
validation
process
Cut-off of 6 0.888
(0.874 to 0.903) 
n=7250
0.883
(0.870 to 0.895) 
n=20 197
0.731
(0.709 to  0.752) 
n=8814
0.957
(0.950 to 0.963) 
n=18 633
0.884
(0.875 to 0.893) 
n=27 447
0.952
Cut-off of 10 0.637
(0.587 to 0.686) 
n=950
0.992
(0.990 to 0.994) 
n=26 497
0.746
(0.694 to 0.798) 
n=811
0.987
(0.984 to 0.990) 
n=26 636
0.980
(0.977 to 0.983) 
n=27 447
0.982
Cross-
validation 
process
Cut-off of 6 0.860
(0.845 to 0.876) 
n=5784
0.873
(0.860 to 0.887) 
n=6969
0.849
(0.833 to 0.866) 
n=5859
0.883
(0.867 to 0.899) 
n=6894
0.867
(0.859 to 0.876) 
n=12 753
Cut-off of 10 0.525
(0.491 to 0.559) 
n=1813
0.986
(0.983 to 0.988) 
n=10 940
0.858
(0.833 to 0.882) 
n=1110
0.926
(0.916 to 0.936) 
n=11 643
0.920
(0.911 to 0.930) 
n=12 753
NPV, negative predictive value; PCC, proportion correctly classified; PPV, positive predictive value; ROC, receiver operating characteristic; Sn, 
sensitivity; Sp, specificity.
excellent Sp and NPV. The cross-validation of sFNAS 
provided a Pearson’s correlation of 0.908 and detected 
adequate values of Sn, Sp, PPV and NPV. To our knowledge, 
this is the first shortened or simplified NAS scoring system 
that provided a cross-validation process.6
The 21-item original FNAS assesses the central nervous 
system, autonomic and gastrointestinal signs of infants 
with NAS. In its development, each of the categories was 
analysed to include the major clinical signs,13 resulting in a 
comprehensive scoring system that included clinically signif-
icant items that were often highly correlated, and thereby 
increasing the number of manifestations to be assessed.20 
Although the sFNAS is shortened to 10 items, it maintains 
more than one item within each category of signs of NAS.
The assessment of the central nervous system signs 
in the sFNAS included four items (cry, tremors, tone 
and sleep) describing neurological excitability. These 
items were also described or included in other scoring 
systems,7 8 13 20 21 with reported prevalence comparable 
to our results. Moro reflex and myoclonic jerks were not 
retained in the sFNAS, but were significantly related to 
items retained in the new scoring system. Seizures are a 
very important sign of NAS, with a high assigned score 
value in the original FNAS; however, its occurrence was 
noted in less than 0.1% of the more than 40 000 observa-
tions that we analysed.
As to autonomic manifestations, nasal stuffiness and 
respiratory rate were the items that contributed most to the 
FNAS and were included in the sFNAS. The respiratory rate 
has been reported to be associated with a lack of respiratory 
control or an abnormal breathing pattern of infants with 
NAS.22 23 Gewolb et al22 found subtle abnormalities in respi-
ratory control and swallow rhythmicity in infants exposed 
to opioids and cocaine. The investigators proposed that in 
utero drug exposure may affect the neuronal development 
and organisation in brainstem areas, resulting in abnor-
malities in the coordination of suck–swallow–respiration. 
Other autonomic manifestations noted in our infants were 
frequent yawning, fever, sneezing and sweating; these were 
rare and/or strongly associated with the manifestations 
included in the sFNAS.
Of the gastrointestinal manifestations, all four items in 
the original FNAS were retained in the sFNAS. Prolonged 
sucking with fewer pauses associated with increased spitting 
episodes has been reported in infants with NAS,13 20 24 25 but 
the significance of these signs remains controversial.22 24 
Loose or watery stools have been reported to be a sign of 
excessive gastrointestinal irritability in infants undergoing 
opioid withdrawal.26 27 The loose or watery stools alone 
contributed notably to the correlation as an independent 
and clinically significant sign in NAS.
There were differences in percentages of occurrences 
of some items between the two institutions in our study. 
Reports indicate variation in the prevalence of the signs 
of NAS across different centres.10 15 20 21 28 Since external 
factors and nurses variability have minimal influence 
on the FNAS,29 we believe that this variability seems to 
be more related to intrinsic neonatal factors. Regardless 
of the difference in percentages of occurrences of some 
items between our institutions, the Pearson’s correlation 
was high with adequate Sn and excellent Sp, PPV, NPV 
and PCC. High Sp and NPV are important for identifying 
infants that should not require pharmacotherapy.
There were other scales developed concomitantly with 
the FNAS. The Ostrea tool30 is a six-item scale that ranks 
multiple NAS signs but with no proposed guide for treat-
ment. The Neonatal Narcotic Withdrawal Index9 was 
designed in 1981 with adequate validity, but it did not 
gain much popularity. The Narcotic Withdrawal Score by 
Lipsitz7 in 1975 included 11 items and evaluated infants 
twice daily. The tool proposed to initiate treatment when 
one score is greater than 4. However, studies have shown 
that a high score may not necessarily be obtained in 
subsequent assessments. Therefore, consecutive scores 
meeting cut-off would be pertinent to initiate pharmaco-
logical treatment.1 17
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There were previous attempts to modify the Finnegan 
scoring system.27 The Neonatal Withdrawal Inventory8 
proposed an 8-point checklist that was derived from 
the FNAS with reported inter-rater reliability, sensitivity 
and specificity; however, the scoring system was not vali-
dated. Jansson et al25 developed a new scoring system 
(MOTHER NAS scale), adding and removing items to 
the FNAS to create a 19-item scale, recommending treat-
ment on scores ≥9. This score was used in the Maternal 
Opioid Treatment: Human Experimental Research 
(MOTHER) project.31 Subsequently, it was modified 
to develop a short screening tool32; its validation awaits 
further studies. In 2015, institution 2 started assessing 
infants with NAS using the MOTHER NAS scale. 
From a data set of 17 150 observations in 276 infants 
over a period of 1 year, the sFNAS compared with the 
MOTHER NAS scale resulted in a Pearson’s correlation 
of 0.86. The sFNAS showed Sn=0.96, Sp=0.80, PPV=0.55, 
NPV=0.99 and PCC=0.83 to predict scores ≥9 on the 
MOTHER NAS scale. This correlation between the 
sFNAS and the MOTHER NAS scale is another support 
for the potential utility of the sFNAS in the assessment 
of NAS.
In 2013, Maguire et al18 reported on an FNAS-short 
form. They performed factor analysis and their proposed 
scale contained seven items with a reported Pearson’s 
correlation of 0.917 with their original data set. Since this 
score is very similar to ours, we applied it to our data sets. 
The correlation between their seven-item score and the 
original FNAS score was 0.818 and 0.811 for institutions 
1 and 2, respectively, which is lower than our correlations 
of 0.914 and 0.908 for institutions 1 and 2, respectively. 
This difference may be attributed to having more items 
included in the sFNAS.
As to limitations, the sFNAS was solely derived to 
shorten the original FNAS and not to improve on the 
psychometric properties of the original tool.33 Our 
study did not include a prospective clinical evaluation 
of inter-rater reliability, and therefore this will need 
to be addressed in future studies. Also, our study was 
not designed to determine the utility of the sFNAS in 
adjusting doses for pharmacological treatment; this is 
the next logical step after prospectively establishing 
its inter-rater reliability, sensitivity and specificity as a 
tool for initiation of treatment. Future studies should 
also include determination of the proportion of infants 
correctly classified as meeting threshold cut-offs from 
both the sFNAS and the original FNAS, as well as the 
percentage of those with discrepant scores. Indeed, 
the lack of uniformity in the assessment of infants with 
NAS2 5 10 11 28 34 can complicate the clinical care and 
increase the hospital costs for the affected infants.
cOnclusIOn
The sFNAS provides a shortened and simplified assess-
ment for infants with NAS. Developed with a rigorous 
statistical approach and with cross-validation, the sFNAS 
is not only abbreviated, but easily administered with 
minimal handling or interaction with the infant. The 
sFNAS having a high correlation with the original FNAS 
and with the MOTHER NAS scale makes it an attractive, 
efficient and simple alternative to the use of these lengthy 
tools. Further studies are needed to establish clinical 
utility, validity and reliability prior to a widespread appli-
cation of the sFNAS.
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